{"pmid":32501877,"title":"Kinetic patterns of liver enzyme elevation with COVID-19 in the USA.","text":["Kinetic patterns of liver enzyme elevation with COVID-19 in the USA.","COVID-19 is a global pandemic that started in Wuhan, China. COVID-19 related liver enzyme elevations have been described however the clinical presentation, enzyme kinetics, and associated laboratory abnormalities of these patients have not been well described. Five cases of COVID-19 associated liver enzyme elevations are reported here. We found that COVID-19 related liver enzyme elevations occurred in a hepatocellular pattern and persisted throughout the initial hospitalization in all patients. Abnormalities in lactate dehydrogenase and ferritin levels were seen in all five cases. In conclusion, abnormalities in aminotransferase, lactate dehydrogenase, and ferritin levels are commonly seen in COVID-19 related liver injury. Elevated aminotransferase levels often persist throughout the entire hospitalization. However, the clinical course of COVID-19 related liver injury appears benign.","Eur J Gastroenterol Hepatol","Da, Ben L","Mitchell, Robert A","Lee, Brian T","Perumalswami, Ponni","Im, Gene Y","Agarwal, Ritu","Schiano, Thomas D","Dieterich, Douglas","Saberi, Behnam","32501877"],"abstract":["COVID-19 is a global pandemic that started in Wuhan, China. COVID-19 related liver enzyme elevations have been described however the clinical presentation, enzyme kinetics, and associated laboratory abnormalities of these patients have not been well described. Five cases of COVID-19 associated liver enzyme elevations are reported here. We found that COVID-19 related liver enzyme elevations occurred in a hepatocellular pattern and persisted throughout the initial hospitalization in all patients. Abnormalities in lactate dehydrogenase and ferritin levels were seen in all five cases. In conclusion, abnormalities in aminotransferase, lactate dehydrogenase, and ferritin levels are commonly seen in COVID-19 related liver injury. Elevated aminotransferase levels often persist throughout the entire hospitalization. However, the clinical course of COVID-19 related liver injury appears benign."],"journal":"Eur J Gastroenterol Hepatol","authors":["Da, Ben L","Mitchell, Robert A","Lee, Brian T","Perumalswami, Ponni","Im, Gene Y","Agarwal, Ritu","Schiano, Thomas D","Dieterich, Douglas","Saberi, Behnam"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501877","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1097/MEG.0000000000001792","locations":["Wuhan","China","USA"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668890966350626816,"score":9.490897,"similar":[{"pmid":32483005,"title":"Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study.","text":["Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study.","INTRODUCTION: Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. METHODS: Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. RESULTS: Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0-55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2-6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11-16). No differences in disease severity and clinical outcomes were noted between the groups. DISCUSSION: We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19.","Am J Gastroenterol","Hao, Shao-Rui","Zhang, Shan-Yan","Lian, Jiang-Shan","Jin, Xi","Ye, Cheng-Yin","Cai, Huan","Zhang, Xiao-Li","Hu, Jian-Hua","Zheng, Lin","Zhang, Yi-Min","Jia, Hong-Yu","Yu, Guo-Dong","Wang, Xiao-Yan","Gu, Jue-Qing","Lu, Ying-Feng","Yu, Xiao-Peng","Yu, Liang","Xiang, Dai-Rong","Ye, Chan-Yuan","Jin, Ci-Liang","Qiu, Yun-Qing","Li, Lan-Juan","Sheng, Ji-Fang","Liang, Ting-Bo","Yang, Yi-Da","32483005"],"abstract":["INTRODUCTION: Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. METHODS: Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. RESULTS: Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0-55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2-6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11-16). No differences in disease severity and clinical outcomes were noted between the groups. DISCUSSION: We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19."],"journal":"Am J Gastroenterol","authors":["Hao, Shao-Rui","Zhang, Shan-Yan","Lian, Jiang-Shan","Jin, Xi","Ye, Cheng-Yin","Cai, Huan","Zhang, Xiao-Li","Hu, Jian-Hua","Zheng, Lin","Zhang, Yi-Min","Jia, Hong-Yu","Yu, Guo-Dong","Wang, Xiao-Yan","Gu, Jue-Qing","Lu, Ying-Feng","Yu, Xiao-Peng","Yu, Liang","Xiang, Dai-Rong","Ye, Chan-Yuan","Jin, Ci-Liang","Qiu, Yun-Qing","Li, Lan-Juan","Sheng, Ji-Fang","Liang, Ting-Bo","Yang, Yi-Da"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483005","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.14309/ajg.0000000000000717","locations":["Zhejiang","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668704334388396032,"score":284.78842},{"pmid":32437830,"title":"SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.","text":["SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.","BACKGROUND: Liver enzyme abnormality is common in patients with coronavirus disease 2019 (COVID-19). Whether or not SARS-CoV-2 infection can lead to liver damage per se remains unknown. Here we reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with liver enzyme abnormality. METHODS: We received 156 patients diagnosed of COVID-19 from two designated centers in China, and compared clinical features between patients with elevated aminotransferase or not. Postmortem liver biopsies were obtained from two cases who had elevated aminotransferase. We investigated the patterns of liver impairment by electron microscopy, immunohistochemistry, TUNEL assay, and pathological studies. RESULTS: 64 of 156 (41.0%) COVID-19 patients had elevated aminotransferase. The median levels of ALT were 50 U/L vs. 19 U/L, respectively, AST were 45.5 U/L vs. 24 U/L, respectively in abnormal and normal aminotransferase groups. The liver enzyme abnormality was associated with disease severity, as well as a series of laboratory tests including higher A-aDO2, higher GGT, lower albumin, decreased CD4+ T cells and B lymphocytes. Ultrastructural examination identified typical coronavirus particles characterized by spike structure in cytoplasm of hepatocytes in two COVID-19 cases. SARS-CoV-2 infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation, and glycogen granule decrease. Histologically, massive hepatic apoptosis and a certain binuclear hepatocytes were observed. Taken together, both ultrastructural and histological evidence indicated a typical lesion of viral infection. Immunohistochemical results showed scanty CD4+ and CD8+ lymphocytes. No obvious eosinophil infiltration, cholestasis, fibrin deposition, granuloma, massive central necrosis, or interface hepatitis were observed. CONCLUSIONS: SARS-CoV-2 infection in liver is a crucial cause of hepatic impairment in COVID-19 patients. Hence, a surveillance of viral clearance in liver and long outcome of COVID-19 is required.","J Hepatol","Wang, Yijin","Liu, Shuhong","Liu, Hongyang","Li, Wei","Lin, Fang","Jiang, Lina","Li, Xi","Xu, Pengfei","Zhang, Lixin","Zhao, Lihua","Cao, Yun","Kang, Jiarui","Yang, Jianfa","Li, Ling","Liu, Xiaoyan","Li, Yan","Nie, Ruifang","Mu, Jinsong","Lu, Fengmin","Zhao, Shousong","Lu, Jiangyang","Zhao, Jingmin","32437830"],"abstract":["BACKGROUND: Liver enzyme abnormality is common in patients with coronavirus disease 2019 (COVID-19). Whether or not SARS-CoV-2 infection can lead to liver damage per se remains unknown. Here we reported the clinical characteristics and liver pathological manifestations of COVID-19 patients with liver enzyme abnormality. METHODS: We received 156 patients diagnosed of COVID-19 from two designated centers in China, and compared clinical features between patients with elevated aminotransferase or not. Postmortem liver biopsies were obtained from two cases who had elevated aminotransferase. We investigated the patterns of liver impairment by electron microscopy, immunohistochemistry, TUNEL assay, and pathological studies. RESULTS: 64 of 156 (41.0%) COVID-19 patients had elevated aminotransferase. The median levels of ALT were 50 U/L vs. 19 U/L, respectively, AST were 45.5 U/L vs. 24 U/L, respectively in abnormal and normal aminotransferase groups. The liver enzyme abnormality was associated with disease severity, as well as a series of laboratory tests including higher A-aDO2, higher GGT, lower albumin, decreased CD4+ T cells and B lymphocytes. Ultrastructural examination identified typical coronavirus particles characterized by spike structure in cytoplasm of hepatocytes in two COVID-19 cases. SARS-CoV-2 infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation, and glycogen granule decrease. Histologically, massive hepatic apoptosis and a certain binuclear hepatocytes were observed. Taken together, both ultrastructural and histological evidence indicated a typical lesion of viral infection. Immunohistochemical results showed scanty CD4+ and CD8+ lymphocytes. No obvious eosinophil infiltration, cholestasis, fibrin deposition, granuloma, massive central necrosis, or interface hepatitis were observed. CONCLUSIONS: SARS-CoV-2 infection in liver is a crucial cause of hepatic impairment in COVID-19 patients. Hence, a surveillance of viral clearance in liver and long outcome of COVID-19 is required."],"journal":"J Hepatol","authors":["Wang, Yijin","Liu, Shuhong","Liu, Hongyang","Li, Wei","Lin, Fang","Jiang, Lina","Li, Xi","Xu, Pengfei","Zhang, Lixin","Zhao, Lihua","Cao, Yun","Kang, Jiarui","Yang, Jianfa","Li, Ling","Liu, Xiaoyan","Li, Yan","Nie, Ruifang","Mu, Jinsong","Lu, Fengmin","Zhao, Shousong","Lu, Jiangyang","Zhao, Jingmin"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437830","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jhep.2020.05.002","keywords":["covid-19","cytopathy","liver enzyme abnormality","sars-cov-2 infection"],"locations":["China","TUNEL","granuloma"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Glycogen"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393517920256,"score":268.16827},{"pmid":32298767,"pmcid":"PMC7194951","title":"COVID-19: Abnormal liver function tests.","text":["COVID-19: Abnormal liver function tests.","BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3x the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients.","J Hepatol","Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin","32298767"],"abstract":["BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver test results. METHODS: Clinical records and laboratory results were obtained from 417 patients with laboratory-confirmed COVID-19 who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients having alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase levels elevated to more than 3x the upper limit of normal, respectively. Patients with abnormal liver tests of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios [ORs] 2.73; 95% CI 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both p <0.01). CONCLUSION: Patients with abnormal liver tests were at higher risk of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, which should be monitored and evaluated frequently. LAY SUMMARY: Data on liver tests in patients with COVID-19 are scarce. We observed a high prevalence of liver test abnormalities and liver injury in 417 patients with COVID-19 admitted to our referral center, and the prevalence increased substantially during hospitalization. The presence of abnormal liver tests and liver injury were associated with the progression to severe pneumonia. The detrimental effects on liver injury were related to certain medications used during hospitalization, which warrants frequent monitoring and evaluation for these patients."],"journal":"J Hepatol","authors":["Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298767","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.006","keywords":["2019-ncov","bilirubin","critical care","liver injury","liver tests","pneumonia","sars-cov-2"],"locations":["Shenzhen","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Bilirubin"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493221339137,"score":267.13043},{"pmid":32405183,"pmcid":"PMC7212283","title":"Gastrointestinal and Liver Manifestations of COVID-19.","text":["Gastrointestinal and Liver Manifestations of COVID-19.","The worldwide pandemic of COVID-19, caused by the virus SARS-CoV,-2 has continued to progress, and increasing information is becoming available about the incidence of digestive symptoms as well as abnormal liver-associated enzymes in patients who are infected. These are postulated to be related to the virus's use of ACE-2 receptors located on certain intestinal cells, cholangiocytes, and hepatocytes. This brief review summarizes the available limited data on digestive manifestations of COVID-19. A significant proportion of COVID-19 patients can present initially with only digestive complaints. The most common digestive symptoms are anorexia, nausea, vomiting, and diarrhea. Liver-related transaminases are elevated in a substantial proportion of patients, although generally only mildly elevated. Currently there is no firm evidence to suggest that severity of digestive symptoms corresponds to severity of COVID-19 clinical course, however, more severe alterations in liver enzymes may correlate with worse clinical course. Given use of antiviral and antibacterial agents in sicker patients, drug-induced liver injury cannot be ruled out either in these cases. Although viral RNA can be detected in stool, it is unclear whether fecal-oral transmission can be achieved by the virus. As further data becomes available, our understanding of the digestive manifestations of COVID-19 will continue to evolve.","J Clin Exp Hepatol","Agarwal, Amol","Chen, Alan","Ravindran, Nishal","To, Chau","Thuluvath, Paul J","32405183"],"abstract":["The worldwide pandemic of COVID-19, caused by the virus SARS-CoV,-2 has continued to progress, and increasing information is becoming available about the incidence of digestive symptoms as well as abnormal liver-associated enzymes in patients who are infected. These are postulated to be related to the virus's use of ACE-2 receptors located on certain intestinal cells, cholangiocytes, and hepatocytes. This brief review summarizes the available limited data on digestive manifestations of COVID-19. A significant proportion of COVID-19 patients can present initially with only digestive complaints. The most common digestive symptoms are anorexia, nausea, vomiting, and diarrhea. Liver-related transaminases are elevated in a substantial proportion of patients, although generally only mildly elevated. Currently there is no firm evidence to suggest that severity of digestive symptoms corresponds to severity of COVID-19 clinical course, however, more severe alterations in liver enzymes may correlate with worse clinical course. Given use of antiviral and antibacterial agents in sicker patients, drug-induced liver injury cannot be ruled out either in these cases. Although viral RNA can be detected in stool, it is unclear whether fecal-oral transmission can be achieved by the virus. As further data becomes available, our understanding of the digestive manifestations of COVID-19 will continue to evolve."],"journal":"J Clin Exp Hepatol","authors":["Agarwal, Amol","Chen, Alan","Ravindran, Nishal","To, Chau","Thuluvath, Paul J"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405183","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jceh.2020.03.001","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666950579860013056,"score":259.13846},{"pmid":32359177,"title":"Longitudinal association between markers of liver injury and mortality in COVID-19 in China.","text":["Longitudinal association between markers of liver injury and mortality in COVID-19 in China.","Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization.","Hepatology","Lei, Fang","Liu, Ye-Mao","Zhou, Feng","Qin, Juan-Juan","Zhang, Peng","Zhu, Lihua","Zhang, Xiao-Jing","Cai, Jingjing","Lin, Lijin","Ouyang, Shan","Wang, Xiaoming","Yang, Chengzhang","Cheng, Xu","Liu, Weifang","Li, Haomiao","Xie, Jing","Wu, Bin","Luo, Huiming","Xiao, Fei","Chen, Jing","Tao, Liang","Cheng, Gang","She, Zhi-Gang","Zhou, Jianghua","Wang, Haitao","Lin, Jun","Luo, Pengcheng","Fu, Shouzhi","Zhou, Jihui","Ye, Ping","Xiao, Bing","Mao, Weiming","Liu, Liming","Yan, Youqin","Liu, Ling","Chen, Guohua","Li, Hongliang","Huang, Xiaodong","Zhang, Bing-Hong","Yuan, Yufeng","32359177"],"abstract":["Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization."],"journal":"Hepatology","authors":["Lei, Fang","Liu, Ye-Mao","Zhou, Feng","Qin, Juan-Juan","Zhang, Peng","Zhu, Lihua","Zhang, Xiao-Jing","Cai, Jingjing","Lin, Lijin","Ouyang, Shan","Wang, Xiaoming","Yang, Chengzhang","Cheng, Xu","Liu, Weifang","Li, Haomiao","Xie, Jing","Wu, Bin","Luo, Huiming","Xiao, Fei","Chen, Jing","Tao, Liang","Cheng, Gang","She, Zhi-Gang","Zhou, Jianghua","Wang, Haitao","Lin, Jun","Luo, Pengcheng","Fu, Shouzhi","Zhou, Jihui","Ye, Ping","Xiao, Bing","Mao, Weiming","Liu, Liming","Yan, Youqin","Liu, Ling","Chen, Guohua","Li, Hongliang","Huang, Xiaodong","Zhang, Bing-Hong","Yuan, Yufeng"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359177","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/hep.31301","locations":["Hubei","neutrophil","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Bilirubin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495344705537,"score":253.16032}]}